[Prevalence of anti-Toxoplasma gondii antibodies in pregnant women in seven hospitals in Buenos Aires area. Comparison 2006 vs. 2017]. / Prevalencia de anticuerpos anti-Toxoplasma gondii en embarazadas en siete hospitales de Buenos Aires. Comparación entre 2006 y 2017.

We analyzed the presence of IgG and IgM anti-Toxoplasma gondii, as a measure of infection, in pregnant women attending seven hospitals in the Metropolitan Area of Buenos Aires during 2006 and 2017. T. gondii seroprevalence in 2006 vs. 2017, was: Hospital Alemán: 22 and 17% (p = 0.004), Hospital Fiorito: 44 and 33% (p < 0.001), Hospital Gandulfo: 30 and 34% (p 0.025), Hospital Grierson 60 and 44% (p < 0.001), Hospital Rivadavia: 59 and 51% (p = 0.003), Hospital Sardá: 47 and 39% (p < 0.001), and Hospital Thompson: 61 and 51% (p < 0.001). The comparison showed a significant decrease in seroprevalence in six hospitals. We also observed a significant decrease in the reactivity for IgM in 2017 compared to 2006 and in the seroprevalence for T. gondii in the overall population of pregnant women in the study. This means that a greater number of women are susceptible to develop acute infection during pregnancy.

Se analizó de forma retrospectiva la presencia de anticuerpos séricos IgG e IgM anti-Toxoplasma gondii en las embarazadas que concurrieron a siete hospitales del área Metropolitana de Buenos Aires durante 2006 y 2017. La prevalencia de infección, medida como presencia de anticuerpos, en 2006 vs. 2017, fue: Hospital Alemán: 22 y 17% (p = 0.004), Hospital Fiorito: 44 y 33% (p < 0.001), Hospital Gandulfo: 30 y 34% (p 0.025), Hospital Grierson: 60 y 44% (p < 0.001), Hospital Rivadavia: 59 y 51% (p=0.003), Maternidad Sardá 47 y 39% (p < 0.001) y Hospital Thompson: 61 y 51% (p < 0.001). La comparación demostró una disminución estadísticamente significativa de la seroprevalencia en seis hos pitales. También disminuyeron significativamente la reactividad para IgM en 2017 respecto de 2006 y la seroprevalencia para T. gondii en el total de la población de embarazadas estudiadas, lo que significa un mayor número de mujeres susceptible de desarrollar infección aguda durante el embarazo.

Prevalencia de anticuerpos anti-Toxoplasma gondii en embarazadas en siete hospitales de Buenos Aires: Comparación entre 2006 y 2017 / Prevalence of anti-Toxoplasma gondii antibodies in pregnant women in seven hospitals in Buenos Aires area. Comparison 2006 vs. 2017

Se analizó; de forma retrospectiva la presencia de anticuerpos só;©ricos IgG e IgM anti-Toxoplasma gondii en las embarazadas que concurrieron a siete hospitales del ó;rea Metropolitana de Buenos Aires durante 2006 y 2017. La prevalencia de infecció;n, medida como presencia de anticuerpos, en 2006 vs. 2017, fue: Hospital Alemán: 22 y 17% (p = 0.004), Hospital Fiorito: 44 y 33% (p < 0.001), Hospital Gandulfo: 30 y 34% (p 0.025), Hospital Grierson: 60 y 44% (p < 0.001), Hospital Rivadavia: 59 y 51% (p=0.003), Maternidad Sardá 47 y 39% (p < 0.001) y Hospital Thompson: 61 y 51% (p < 0.001). La comparació;n demostró; una disminució;n estadísticamente significativa de la seroprevalencia en seis hos pitales. Tambín disminuyeron significativamente la reactividad para IgM en 2017 respecto de 2006 y la seroprevalencia para T. gondii en el total de la població;n de embarazadas estudiadas, lo que significa un mayor nó;ºmero de mujeres susceptible de desarrollar infecció;n aguda durante el embarazo.

We analyzed the presence of IgG and IgM anti- Toxoplasma gondii, as a measure of infection, in pregnant women attending seven hospitals in the Metropolitan Area of Buenos Aires during 2006 and 2017. T. gondii seroprevalence in 2006 vs. 2017, was: Hospital Alemán: 22 and 17% (p = 0.004), Hospital Fiorito: 44 and 33% (p < 0.001), Hospital Gandulfo: 30 and 34% (p 0.025), Hospital Grierson 60 and 44% (p < 0.001), Hospital Rivadavia: 59 and 51% (p = 0.003), Hospital Sardá: 47 and 39% (p < 0. 001), and Hospital Thompson: 61 and 51% (p < 0.001). The comparison showed a significant decrease in seroprevalence in six hospitals. We also observed a significant decrease in the reactivity for IgM in 2017 compared to 2006 and in the seroprevalence for T. gondii in the overall population of pregnant women in the study. This means that a greater number of women are susceptible to develop acute infection during pregnancy.

Estudio multicéntrico para la prevención de la toxoplasmosis prenatal en Buenos Aires / Multicenter study on the prevention of congenital toxoplasmosis in Buenos Aires

La toxoplasmosis es una infección causada por Toxoplasma gondii, parásito intracelular de distribución universal cuya tasa de seroprevalencia varía según la región. En el feto o recién nacido la infección causa morbilidad y mortalidad. El presente trabajo es una evaluación práctica de las propuestas del Consenso Argentino de Prevención de la Toxoplasmosis Prenatal. Participaron 9 hospitales de Buenos Aires y Conurbano donde se atendieron 19825 partos entre el 1º de mayo del 2006 y el 30 de abril del 2007. Se realizaron pruebas de tamizaje serológico en 13632 embarazadas con determinaciones de IgG e IgM por método de ELISA. La prevalencia de anticuerpos IgG específicos anti Toxoplasma gondii fue del 49%. Los sueros clasificados con criterio de infección reciente se remitieron al laboratorio del Hospital Alemán para ampliar el estudio. A los recién nacidos de estas madres se les efectuó control clínico y serológico. El análisis de los resultados de las 351 muestras enviadas confirmó que 121 (32%) pacientes podrían haberse infectado durante el embarazo, en 176 (46%) se descartó la infección reciente, en 37 embarazadas (10%) la serología no fue concluyente y en 47 (12%) faltó la fecha de gestación para su interpretación. Se efectuó control clínico y serológico a 94 recién nacidos de madres con infección durante el embarazo y se detectaron 5 toxoplasmosis congénitas con daño fetal, una microcefalia y cuatro coriorretinitis. El estudio permitió validar las guías y recomendaciones del Consenso Argentino de Toxoplasmosis Congénita.

Toxoplasmosis is an infection caused by Toxoplasma gondii, an intracellular parasite of universal distribution, with a variable prevalence depending on the region. This infection causes both morbidity and mortality in the fetus and newborn. The present study is an evaluation of the Argentine Consensus Guidelines regarding prenatal prevention of toxoplasmosis. Screening tests in pregnant women were done in nine different hospitals within the city of Buenos Aires and surroundings, where 19825 births between May 1st 2006 and April 30th 2007 were registered. Screening tests were done in 13632 pregnant women, using IgG and IgM determinations by ELISA. If acute infection was suspected, the patient‘s serum was sent to the reference laboratory to fulfill the pending tests: Sabin Feldman, ISAGA M, ISAGA A, ISAGA E and avidity. Clinical and serologic evaluation was done to all newborn of these mothers. Three hundred and fifty one specimens were sent and analyzed. Conclusions from the analysis were as follows: 121 (32%) patients probably acquired the infection during pregnancy, in 176 (46%) patients, acute infection was excluded, in 37 women (10%) serologic results were inconclusive, and in 47 (12%) the interpretation of results was impossible due to lack of information on the exact gestational age. Clinical and serologic control was performed in 94 newborns of mothers infected during pregnancy, and 5 congenital toxoplasmosis were detected, with fetal damage, four corioretinitis and one case of microcephaly. This study allowed us to validate the Argentine Consensus of Congenital Toxoplasmosis Guidelines.

[Multicenter study on the prevention of congenital toxoplasmosis in Buenos Aires]. / Estudio multicéntrico para la prevención de la toxoplasmosis prenatal en Buenos Aires.

Toxoplasmosis is an infection caused by Toxoplasma gondii, an intracellular parasite of universal distribution, with a variable prevalence depending on the region. This infection causes both morbidity and mortality in the fetus and newborn. The present study is an evaluation of the Argentine Consensus Guidelines regarding prenatal prevention of toxoplasmosis. Screening tests in pregnant women were done in nine different hospitals within the city of Buenos Aires and surroundings, where 19825 births between May 1st 2006 and April 30th 2007 were registered. Screening tests were done in 13632 pregnant women, using IgG and IgM determinations by ELISA. If acute infection was suspected, the patient's serum was sent to the reference laboratory to fulfill the pending tests: Sabin Feldman, ISAGA M, ISAGA A, ISAGA E and avidity. Clinical and serologic evaluation was done to all newborn of these mothers. Three hundred and fifty one specimens were sent and analyzed. Conclusions from the analysis were as follows: 121 (32%) patients probably acquired the infection during pregnancy, in 176 (46%) patients, acute infection was excluded, in 37 women (10%) serologic results were inconclusive, and in 47 (12%) the interpretation of results was impossible due to lack of information on the exact gestational age. Clinical and serologic control was performed in 94 newborns of mothers infected during pregnancy, and 5 congenital toxoplasmosis were detected, with fetal damage, four corioretinitis and one case of microcephaly. This study allowed us to validate the Argentine Consensus of Congenital Toxoplasmosis Guidelines.